The CRML Mines to Metals begins marking a significant move in the rare earth industry to full supply chain control

NEW YORK, Sept. 16, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals” or the “Company”), a leading critical minerals mining company, today announced further details of its mine-to-metals strategy aimed at maximizing supply-chain security and the potential value derived from the Tanbreez Rare Earth Project in Greenland.

The proposed CRML Romanian joint venture refinery, which is expected to receive 50% of all concentrate production under the existing term sheet, incorporates three major process innovations that are projected to enhance project economics:

  • Multistage mixed-acid reactor additions designed to prevent silica gel formation, a challenge encountered in other eudialyte processing routes. (Patent pending)
  • Complete silica recovery through off-gas recovery, designed to produce 99.99% SiO2 powder, reduce tailings to less than 1.5% of feed material and recycle acid, potentially reducing fresh acid consumption by approximately 85% while generating an additional high-value product stream;
  • Vacuum freeze-drying (lyophilisation) of all 19 chloride salts, designed to produce anhydrous, ultra-low-moisture powders that may command price premiums over conventionally dried material.

The proposed CRML Romania Process Refinery is being designed with capacity to process up to 100,000 tons per year of eudialyte concentrate feed and based on current modelling, produce approximately 27,943 tons per year of rare earth and critical metal products in the form of chloride salts and other ultra-pure products.

Projected by-products include 25,670 tons per year of high purity SiO2 powder.

Based on current modelling and assumed market pricing, projected annual revenue from the silica by-product could reach approximately US$600 million.

The current preliminary CAPEX estimate is US$1,85 billion (+/-25% Class 4 estimate).

Current modelling projects annual revenue of approximately US$2,2 billion before operating costs, taxes and capital recovery.

Current modelling indicates an NPV10 of approximately US$4.5 billion, an IRR of approximately 55% and a projected payback period of approximately two years.

The silicate recovery system is projected to contribute approximately US$400-600 million per year in combined value from SiO2 revenue and avoided acid costs, potentially transforming a conventional waste stream into a significant revenue contributor. Based on current modelling and pricing assumptions key value drivers include SiO2, NbCl5, DyCl3, TaCl5 and Hafnium products.

The proposed CRML Romania Process Refinery uses a multistage, mixed-acid leach process operating at elevated temperatures, followed by cascading recovery steps designed to produce high-purity rare earth salts, metals and critical metal salts for advanced industrial, aerospace, technology and defense applications.

A key feature of the proposed process is the recovery of materials that would traditionally report to tailings, including silica and potentially alumina, iron and copper. Current process modelling targets a tailings stream of approximately 1% of feed tonnage, supporting the Company’s objective of developing a lower-waste processing route.

The proposed process route then through a multistage ion-exchange system, with multiple recovery stages for individual elements, designed to achieve high-purity products in the 99.9-99.99% range, subject to further test work and process validation.

The proposed production route for high-purity hafnium products utilizes established processing technologies. Based on current modelling, CRML Romania could produce approximately 50-70 tons per annum of high-purity hafnium metal during its first five years, together with approximately 20-30 tons per annum of high-purity hafnium chloride. These projections remain subject to further engineering, metallurgical test work, market conditions, permitting and final investment decisions.

The proposed CRML Romania Process Refinery is currently estimated to require up to 150 MW of energy input from gas and/or electricity. Current design assumptions contemplate approximately 60-70% of energy demand being supplied by gas-fired kilns and boilers and approximately 30-40% by third-party or state electricity suppliers.

The proposed CRML Romania Process Refinery is being designed as a low-wastewater and low-tailings operation. Current modelling targets refinery tailings of approximately 1% of input tonnage and limited wastewater discharge, subject to further engineering, environmental studies and permitting. Potential treatment pathways include third-party or approved government facilities in Romania.

Multiple acids and ammonia are expected be generated onsite, with certain high-purity feed materials to be sourced from suppliers in Europe or the United States. The proposed supply strategy is intended to support a secure Western supply chain.

Locating the proposed refinery in Romania, an EU and NATO member state, is intended to support a secure Western supply chain. Current planning contemplates multiple shipping and rail routes for the movement of Tanbreez concentrate from Greenland to the proposed refinery location in Romania.

If developed as currently contemplated, CRML Romania has the potential to become a significant Western supplier of rare earths and critical metals.

The following tables present projected refinery product values based on current modelling, assumed market prices and estimated market demand. These projections are preliminary and remain subject to further engineering, test work, market conditions and completion of feasibility studies.

Current modelling assumes a Tanbreez eudialyte concentrate transfer or sales value of approximately US$4,000 per ton. The refinery model indicates potential revenue of up to approximately US$24,000 per ton of concentrate processed, before operating costs currently estimated at approximately US$3,500-4,000 per ton and before capital recovery, taxes and other costs.

For the base-case economic analysis, current modelling assumes revenue of approximately US$13,000 per ton of eudialyte concentrate processed, using lower historical market pricing assumptions, resulting in approximately US$9,000 per ton before tax and capital recovery based on the current model.

The higher-price case uses 2025-2026 market pricing assumptions of approximately US$24,000 per ton of concentrate processed, resulting in approximately US$20,000 per ton before tax and capital recovery based on the current model. These figures are preliminary modelling assumptions and are subject to commodity prices, recoveries, operating costs, capital costs and further feasibility work.

Tony Sage, Executive Chairman and CEO of Critical Metals Corp., commented:

“This represents a significant evolution in the Tanbreez value proposition and reinforces our commitment to a true mine-to-metals strategy. By combining Tanbreez’s exceptional eudialyte resource with advanced processing in Romania, we have the potential to capture substantially more value from every ton of material while producing the high-purity rare earths and critical metals that Western markets increasingly require.

Importantly, our proposed process is designed to recover valuable by-products such as high-purity silica rather than treating them as waste, potentially improving both the economic and environmental profile of the operation. We believe this integrated approach has the potential to establish Critical Metals Corp. as an important non-Chinese supplier of critical materials to the European and U.S. markets, with Tanbreez providing the resource foundation and the proposed Romanian refinery delivering the downstream value.”

Critical Metals Corp

Fig. 1. Projected Revenue Table and Rare Earth and Critical Metal Production, Excluding By-products

Critical Metals Corp

Fig. 2. Rare Earth Element Distribution

Critical Metals Corp

Fig. 3. Rare Earth Distribution in Tanbreez Concentrate

Critical Metals Corp

Fig. 4. Illustrative Example of a Rare Earth Processing Plant
Source: Getty Images – Pensana’s rare earth refinery at Saltend Chemicals Park. Image is illustrative only and is not the proposed CRML Romania refinery.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next generation technologies for Europe and its western world partners. Its flagship Project, Tanbreez, is one of the world’s largest, rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: ir@criticalmetalscorp.com

Media: pr@criticalmetalscorp.com

Photos accompanying this announcement are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/55640db4-cebc-4ebb-9622-7603bdbfc1e4
https://www.globenewswire.com/NewsRoom/AttachmentNg/de724907-0b33-41af-a7a4-5eca67228213
https://www.globenewswire.com/NewsRoom/AttachmentNg/f5411e9f-7a76-4171-bf20-453b0132e6f1
https://www.globenewswire.com/NewsRoom/AttachmentNg/5e1241cd-b80d-4b3f-9383-2e34adf8a4ff

16 SEPTEMBER 2026

NORTHERN VENTURE TRUST PLC

PUBLICATION OF AN OFFER DOCUMENT

Northern Venture Trust PLC (“the Company”) announces that, in conjunction with Northern 2 VCT PLC and Northern 3 VCT PLC (together with the Company known as “the Northern VCTs”), it has published an offer document (“the Offer Document”) in relation to offers of new ordinary shares for subscription in the 2026/27 tax year (“the Offers”). The Offers seek to raise £10 million for each of the Company, Northern 2 VCT PLC and Northern 3 VCT PLC, £30 million in aggregate.

The Offers will open to applications at 8.00am on 30 September 2026 and applications for new shares in the Company will be dealt with on a “first-come, first-served” basis. In recognition of the loyalty of the Northern VCT shareholders, existing shareholders on the register of members of any of the Northern VCTs as at 10 June 2026, along with their spouse or civil partner, whose applications for shares in any of the Northern VCTs are accepted, will benefit from a reduction of 0.5% in the offer costs applicable to their subscription. The Offers will remain open until 12 noon on 31 March 2027, unless fully subscribed at an earlier date and subject to the Directors’ right to close any of the Offers at any time. There will be a first allotment at the end of November 2026. To be allocated shares in the first allotment, funded valid applications must be received by 5.00pm on 23 November 2026.

Pursuant to an offer agreement between Mercia Fund Management Limited (“Mercia”), the Northern VCTs’ investment adviser/manager and promoter, the Northern VCTs and others, Mercia will, in respect of the services provided in connection to the Offers, receive up to a maximum of 5.5% (or 3.0% where no commission is payable) of the aggregate amounts of the subscription monies as received by the Northern VCTs pursuant to the Offers (the “Promoter’s Fee”). Pursuant to the offer agreement, Mercia agrees that it will pay all costs, charges, fees and expenses payable by the Northern VCTs or Mercia in connection with, or incidental to, the Offers and the admission of the ordinary shares of the Northern VCTs issued pursuant to the Offers.

Mercia, as the investment adviser of the Company, is a related party of the Company under UK Listing Rule 11.5.3R, and the arrangements to pay the Promoter’s Fee to Mercia (as they relate to each of the Northern VCTs) constitutes a relevant related party transaction of the Company of an adequate size under UK Listing Rule 11.5.4R for UK Listing Rule 8.2.1R(1) to (4) to apply. The board of the Company believes that the transaction is fair and reasonable as far as the shareholders of the Company are concerned and have been provided with written confirmation of this by Howard Kennedy Corporate Services LLP as sponsor to the Company.

The Offer Document, describing the key features of the Offers will be sent to registered shareholders in accordance with their communication preferences, as soon as possible.

A downloadable version of the Offer Document is available from: www.mercia.co.uk/vct-share-offers/. Additionally, a copy is available free of charge, from the Company’s registered office at Forward House, 17 High Street, Henley-in-Arden B95 5AA or by calling Mercia on 0330 223 1430.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

16 SEPTEMBER 2026

NORTHERN 2 VCT PLC

PUBLICATION OF AN OFFER DOCUMENT

Northern 2 VCT PLC (“the Company”) announces that, in conjunction with Northern Venture Trust PLC and Northern 3 VCT PLC (together with the Company known as “the Northern VCTs”), it has published an offer document (“the Offer Document”) in relation to offers of new ordinary shares for subscription in the 2026/27 tax year (“the Offers”). The Offers seek to raise £10 million for each of the Company, Northern Venture Trust PLC and Northern 3 VCT PLC, £30 million in aggregate.

The Offers will open to applications at 8.00am on 30 September 2026 and applications for new shares in the Company will be dealt with on a “first-come, first-served” basis. In recognition of the loyalty of the Northern VCT shareholders, existing shareholders on the register of members of any of the Northern VCTs as at 10 June 2026, along with their spouse or civil partner, whose applications for shares in any of the Northern VCTs are accepted, will benefit from a reduction of 0.5% in the offer costs applicable to their subscription. The Offers will remain open until 12 noon on 31 March 2027, unless fully subscribed at an earlier date and subject to the Directors’ right to close any of the Offers at any time. There will be a first allotment at the end of November 2026. To be allocated shares in the first allotment, funded valid applications must be received by 5.00pm on 23 November 2026.

Pursuant to an offer agreement between Mercia Fund Management Limited (“Mercia”), the Northern VCTs’ investment adviser/manager and promoter, the Northern VCTs and others, Mercia will, in respect of the services provided in connection to the Offers, receive up to a maximum of 5.5% (or 3.0% where no commission is payable) of the aggregate amounts of the subscription monies as received by the Northern VCTs pursuant to the Offers (the “Promoter’s Fee”). Pursuant to the offer agreement, Mercia agrees that it will pay all costs, charges, fees and expenses payable by the Northern VCTs or Mercia in connection with, or incidental to, the Offers and the admission of the ordinary shares of the Northern VCTs issued pursuant to the Offers.

Mercia, as the investment manager of the Company, is a related party of the Company under UK Listing Rule 11.5.3R, and the arrangements to pay the Promoter’s Fee to Mercia (as they relate to each of the Northern VCTs) constitutes a relevant related party transaction of the Company of an adequate size under UK Listing Rule 11.5.4R for UK Listing Rule 8.2.1R(1) to (4) to apply. The board of the Company believes that the transaction is fair and reasonable as far as the shareholders of the Company are concerned and have been provided with written confirmation of this by Howard Kennedy Corporate Services LLP as sponsor to the Company.

The Offer Document, describing the key features of the Offers will be sent to registered shareholders in accordance with their communication preferences, as soon as possible.

A downloadable version of the Offer Document is available from: www.mercia.co.uk/vct-share-offers/. Additionally, a copy is available free of charge, from the Company’s registered office at Forward House, 17 High Street, Henley-in-Arden B95 5AA or by calling Mercia on 0330 223 1430.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

16 SEPTEMBER 2026

NORTHERN 3 VCT PLC

PUBLICATION OF AN OFFER DOCUMENT

Northern 3 VCT PLC (“the Company”) announces that, in conjunction with Northern Venture Trust PLC and Northern 2 VCT PLC (together with the Company known as “the Northern VCTs”), it has published an offer document (“the Offer Document”) in relation to offers of new ordinary shares for subscription in the 2026/27 tax year (“the Offers”). The Offers seek to raise £10 million for each of the Company, Northern Venture Trust PLC and Northern 2 VCT PLC, £30 million in aggregate.

The Offers will open to applications at 8.00am on 30 September 2026 and applications for new shares in the Company will be dealt with on a “first-come, first-served” basis. In recognition of the loyalty of the Northern VCT shareholders, existing shareholders on the register of members of any of the Northern VCTs as at 10 June 2026, along with their spouse or civil partner, whose applications for shares in any of the Northern VCTs are accepted, will benefit from a reduction of 0.5% in the offer costs applicable to their subscription. The Offers will remain open until 12 noon on 31 March 2027, unless fully subscribed at an earlier date and subject to the Directors’ right to close any of the Offers at any time. There will be a first allotment at the end of November 2026. To be allocated shares in the first allotment, funded valid applications must be received by 5.00pm on 23 November 2026.

Pursuant to an offer agreement between Mercia Fund Management Limited (“Mercia”), the Northern VCTs’ investment adviser/manager and promoter, the Northern VCTs and others, Mercia will, in respect of the services provided in connection to the Offers, receive up to a maximum of 5.5% (or 3.0% where no commission is payable) of the aggregate amounts of the subscription monies as received by the Northern VCTs pursuant to the Offers (the “Promoter’s Fee”). Pursuant to the offer agreement, Mercia agrees that it will pay all costs, charges, fees and expenses payable by the Northern VCTs or Mercia in connection with, or incidental to, the Offers and the admission of the ordinary shares of the Northern VCTs issued pursuant to the Offers.

Mercia, as the investment manager of the Company, is a related party of the Company under UK Listing Rule 11.5.3R, and the arrangements to pay the Promoter’s Fee to Mercia (as they relate to each of the Northern VCTs) constitutes a relevant related party transaction of the Company of an adequate size under UK Listing Rule 11.5.4R for UK Listing Rule 8.2.1R(1) to (4) to apply. The board of the Company believes that the transaction is fair and reasonable as far as the shareholders of the Company are concerned and have been provided with written confirmation of this by Howard Kennedy Corporate Services LLP as sponsor to the Company.

The Offer Document, describing the key features of the Offers will be sent to registered shareholders in accordance with their communication preferences, as soon as possible.

A downloadable version of the Offer Document is available from: www.mercia.co.uk/vct-share-offers/. Additionally, a copy is available free of charge, from the Company’s registered office at Forward House, 17 High Street, Henley-in-Arden B95 5AA or by calling Mercia on 0330 223 1430.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder (“PTSD“). The trial is expected to begin in 2027.

The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters and healthcare workers. Participants will receive the Company’s synthetic MDMA HCl, supplied in two dosage formats, during two supervised sessions combining MDMA and psychotherapy, spaced several weeks apart, with follow-up evaluations after the final session. The primary efficacy endpoint will be change in the Clinician-Administered PTSD Scale (CAPS-5), the standard clinician-rated instrument for assessing PTSD severity.

“On the heels of announcing our Phase 2 trial of natural psilocybin for the treatment of major depressive disorder, we are preparing to advance our synthetic MDMA into an approved Phase 3 trial in PTSD, with the goal of submitting both products for registration,” said Dane Stevens, Optimi’s Chief Executive Officer and Co-Founder. “PTSD and major depressive disorder are large, underserved markets. Millions of patients around the globe continue to struggle despite existing treatments, and veterans and frontline workers carry a disproportionate share of that burden. Psychedelic-assisted therapies have shown promise in helping patients find relief.”

Post-traumatic stress disorder is a mental health condition that can develop after experiencing or witnessing a terrifying, life-threatening, or deeply traumatic event. People with PTSD typically experience severe, persistent distress that significantly disrupts daily functioning. Worldwide, an estimated 70% of people will experience a traumatic event during their lifetime, with an estimated 3.9% of the global population developing the disorder. Many people with PTSD see limited benefit from first-line treatments such as trauma-focused psychotherapy and antidepressants, leaving a pressing need for new therapeutics.

The safety and efficacy of MDMA-assisted therapy to treat PTSD are still under investigation, and none of Optimi’s MDMA drug products have received market authorization from Health Canada. Clinics in Australia have been prescribing MDMA manufactured by Optimi since October 2024.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the proposed clinical trial, the availability and enrolment of patients in the trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the potential benefits of MDMA, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Notice of Annual General Meeting 2026

ANNOUNCEMENT NO. 314
16 September 2026

Notice of Annual General Meeting
Notice is hereby given of the Annual General Meeting, which will be held on Thursday 8 October 2026 at 5.30 p.m.

The general meeting will be held at Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød.

Additional info
Phillip Massie Price, CFO
Telefon (+45) 81 10 06 80

About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies. ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Attachment

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies 

U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation

CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation and MAIA has activated 3 sites in the U.S.

MAIA holds FDA Fast Track designation for ateganosine, a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. Prior data from THIO-101 Parts A and B show overall survival (OS) beyond 24 months in eight patients receiving ateganosine sequenced with a checkpoint inhibitor.

“We have worked diligently to advance ateganosine into the U.S. market, and dosing the first patient in the United States represents a major milestone for our ongoing Phase 2 clinical trial,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “Our collaborations with some of the nation’s top institutions and foremost oncologists further strengthen the trial as we evaluate ateganosine for patients in advanced stages of this exceedingly hard-to-treat disease. We believe the data generated through the THIO-101 program may also support a potential pathway toward FDA accelerated approval. With patients now enrolled across four continents, the study has evolved into a truly global effort focused on addressing a critical unmet need in cancer care.”

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (NASDAQ: VIVS) (“VivoSim” or the “Company”) unveils new clinical benchmark data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, demonstrating the ability of its NAMkind™ 3D human liver and intestinal platforms to predict drug toxicity across small molecules and increasingly complex therapies, including Antibody-Drug Conjugates (ADCs).

The new data strengthens VivoSim’s positioning in the growing market for human-relevant predictive toxicology and New Approach Methodologies (NAMs), as pharmaceutical companies increasingly look for better ways to identify safety risks before drug candidates enter expensive human clinical trials.

Drug-induced liver injury (DILI) and gastrointestinal (GI) toxicity remain leading causes of drug candidate attrition, while ADC therapies introduce additional safety challenges involving payload toxicity, linker behavior and off-target exposure. VivoSim’s EUROTOX findings demonstrate how its long-duration, primary human cell-based models can help identify and differentiate these risks earlier in development, successfully ranking clinical safety risks for small-molecule reference sets such as thiazolidinediones and NSAIDs, while deconvoluting complex structural toxicities in advanced ADC modalities.

NAMkind™ Targets Liver and GI Toxicity Before the Clinic

VivoSim’s NAMkind™ Liver platform supports up to 28-day liver spheroid viability, while its intestinal models maintain barrier integrity for up to three weeks, allowing researchers to evaluate repeat-dose effects that shorter-duration laboratory assays may not capture.

In studies being presented at EUROTOX, VivoSim’s repeat-dose testing framework successfully ranked clinical safety risks across small-molecule reference compounds while also distinguishing payload- and linker-dependent toxicities in ADCs. The NAMkind™ Liver platform ranked trastuzumab deruxtecan as significantly more hepatotoxic than trastuzumab emtansine in the presented testing. In the NAMkind™ Intestine model, transepithelial electrical resistance (TEER) identified mucosal barrier deterioration before overt tissue cytotoxicity, with human ileum tissue demonstrating greater sensitivity to ADC-induced toxicity than colon tissue.

The findings carry particular weight as ADC development expands across oncology and other therapeutic areas, sharpening demand for technologies capable of determining where toxicity originates and which component of a complex drug is responsible.

Moving Beyond Detecting Toxicity

The broader commercial opportunity for VivoSim goes beyond simply detecting whether a drug candidate is toxic: it lies in helping pharmaceutical developers understand why toxicity occurs and whether it is likely to matter in humans.

“As global regulators like the FDA accelerate the transition away from traditional animal testing, biopharma leaders are seeking predictive human tools that eliminate translational surprises before clinical entry,” said Keith Murphy, Executive Chairman of VivoSim Labs. “Our latest data presented at EUROTOX demonstrate that the NAMkind™ platform doesn’t just evaluate traditional small molecules with exceptional fidelity, it successfully deconvolutes the complex safety liabilities of next-generation modalities like ADCs. By identifying payload and linker toxicities early, we provide our commercial partners with the actionable intelligence needed to save years of development and millions in potential clinical failure.”

“Predicting organ-specific toxicity requires capturing the biology of chronic, repeat-dose exposure,” said Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “With our extended-culture platforms, we observe micro-architectural and functional degradation that traditional short-term assays may miss. Whether ranking clinical DILI risk across small-molecule analogs or pinpointing why trastuzumab deruxtecan exhibits distinct hepatic and ileal liabilities compared to emtansine, our multi-endpoint profiling gives biopharma teams human-relevant translational signatures to optimize compound selection and de-risk pipelines.”

FDA NAM Momentum Adds to the Opportunity

The EUROTOX presentation arrives as regulators, including the U.S. Food and Drug Administration (FDA), continue advancing frameworks for New Approach Methodologies and human-relevant alternatives to traditional animal testing.

That regulatory shift does not represent an endorsement of VivoSim specifically, but it creates a potentially favorable industry backdrop for validated technologies capable of generating predictive human safety information before clinical development.

The opportunity extends beyond detecting toxicity. If broader validation and pharmaceutical adoption follow, NAMkind™ and VitroSense™ could become part of the decision layer between drug discovery and human clinical trials, helping pharmaceutical companies determine which programs deserve additional time and development capital.

For VivoSim investors, the EUROTOX data mark a meaningful validation point in the developing commercial thesis behind NAMkind™ using 3D human biology and predictive toxicology to help pharmaceutical companies identify safety liabilities earlier, select stronger drug candidates and reduce costly failures later in development.

VivoSim’s demonstrated ability to evaluate both traditional small molecules and increasingly important complex modalities such as ADCs positions its NAMkind™ platform to broaden its applications across pharmaceutical R&D.

About VivoSim Labs

VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. 

Contact:
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.

Converse, Indiana, Sept. 16, 2026 (GLOBE NEWSWIRE) — First Farmers Financial Corp. (OTCQX Banks; FFMR), the parent company of First Farmers Bank & Trust Co., announced that on September 15, 2026, the Board of Directors approved a record quarterly cash dividend of $0.27 per share, payable on October 15, 2026, to shareholders of record as of September 30, 2026. This quarterly dividend represents an 8.0% increase over the $0.25 split-adjusted dividend declared in September 2025.

The timing, price, and quantity of purchases under the stock repurchase plan will be at the discretion of management and may be discontinued, suspended, or restarted at any time.  The program will be funded from current available working capital.  The Board feels the stock repurchase plan continues to provide capital management opportunities and add value for the Company’s shareholders depending upon market and business conditions.

First Farmers Financial Corp is a $3.6 billion financial holding company headquartered in Converse, Indiana.  First Farmers Bank & Trust has offices throughout Boone, Carroll, Cass, Clay, Grant, Hamilton, Howard, Huntington, Madison, Marshall, Miami, Starke, Sullivan, Tippecanoe, Tipton, Vigo and Wabash counties in Indiana and offices in Coles, Edgar, and Vermilion counties in Illinois. First Farmers Financial Corp is traded on the OTC Markets Group, Inc. “OTCQX” exchange under the ticker symbol: FFMR  

CONTACT: Tade J Powell
First Farmers Financial Corporation
765-395-3316
tade.powell@ffbt.com

Winners of the 2026 ITEA Awards of Excellence

Winners of the 2026 ITEA Awards of Excellence
Winners of the 2026 ITEA Awards of Excellence

September 16, 2026

  • SYMPHONY receives ITEA’s highest excellence award for connected healthcare ecosystems
  • AI FORSchung is recognized for innovation in AI-powered fiber-optic sensing

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare.

SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for connecting healthcare data, clinical workflows and AI-supported decision tools through open, interoperable ecosystems. AI FORSchung received the ITEA Award of Excellence for Innovation for developing AI-driven methods to compress and analyze large volumes of fiber-optic sensing data. The awards were presented at the ITEA PO Days 2026 in Istanbul, Turkey.

Connecting data and AI around clinical workflows
SYMPHONY developed a reusable, vendor-neutral reference architecture and demonstrated connected healthcare ecosystems across four clinical areas: prostate cancer, aortic aneurysm, atrial fibrillation and multiple sclerosis with clinical partners including Leiden University Medical Center, Amsterdam University Medical Center and Karolinska University Hospital.

Philips also developed technology within SYMPHONY to automatically segment and measure vascular structures in medical images, supporting the assessment and follow-up of aortic aneurysms. The resulting functionality has received FDA clearance and CE marking and is included in AV Vascular, a part of the Philips AV Cardiovascular Suite.

“Healthcare AI creates the greatest value when it can work with the information and clinical workflows that care teams already depend on,” said Sanjay Gandhi, Head of Medical Affairs & Clinical Partnerships at Philips. “SYMPHONY shows what becomes possible when healthcare providers, researchers and technology companies build around open standards and clinical pathways rather than isolated applications.”

This real-world implementation was demonstrated through many close collaborations including the one between Philips and Leiden University Medical Center (LUMC), where standards-based integration was the focus.

“Together with Philips, the LUMC demonstrated in SYMPHONY how vendor-neutral, standards-based integration of clinical data, imaging and applications, including the AV Vascular Segmentation solution, can support real clinical workflows,” said Jouke Dijkstra, Associate Professor, Vascular and Molecular Imaging at LUMC. The project created a reusable foundation for deploying innovative digital health solutions, also tailored towards AI algorithm integration, across institutions and disease areas.”

Making growing sensing datasets more manageable
Fiber Optic RealShape (FORS) technology is used to support medical device navigation during image-guided procedures, generating large volumes of position data that need to be stored and processed efficiently. Within AI FORSchung, researchers developed new methods to make these data volumes easier to manage, demonstrating that FORS position data could be compressed more than 20 times while maintaining performance within the evaluated datasets.

“The challenge extends well beyond healthcare,” said Ahmet Ekin, Senior Designer at Philips. “Fiber-optic sensing is also used to monitor critical infrastructure such as pipelines, bridges and tunnels, where continuous monitoring generates substantial volumes of data. By developing approaches that can be applied across healthcare, utilities and civil infrastructure, AI FORSchung demonstrated how advances in one field can help address shared data challenges in another.

Both projects were conducted within ITEA, the Eureka Research, Development and Innovation Cluster on software innovation, funded by multiple national authorities including the Netherlands Enterprise Agency (RVO).

Additional information about SYMPHONY can be found here: https://itea4.org/project/symphony.html; https://symphony-iteaproject.eu/

Additional information about AI FORSchung can be found here: https://itea4.org/project/ai-forschung.html

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.